ArticleJournal of pain research2026
Combined High-Voltage Long-Duration Pulsed Radiofrequency and Ozone Therapy in the Treatment of Pudendal Neuralgia: A Retrospective Case Series.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the feasibility, safety, and preliminary therapeutic efficacy of combining high-voltage long-duration pulsed radiofrequency with ozone therapy for patients with refractory Pudendal neuralgia (PN). Patients and Methods: Between January 2019 and December 2024, 18 patients diagnosed with PN based on clinical criteria and diagnostic nerve blocks were included after failing or declining conservative therapies. Following informed consent, all patients underwent a single session of high-voltage, long-duration pulsed radiofrequency treatment combined with ozone therapy, followed by supplementary ozone therapy during hospitalization. Outcomes were assessed using the Visual Analog Scale (VAS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Pittsburgh Sleep Quality Index (PSQI), and SF-36 Health Survey at baseline, 1 week, 4 weeks, 12 weeks, and 24 weeks post-treatment by an independent assessor blinded to clinical details. The primary endpoint was the proportion of patients achieving ≥50% reduction in VAS pain score. Results: Fifteen patients completed follow-up (three lost to follow-up). At 12 weeks, 93.3% (14/15); achieved the primary endpoint, one patient had persistent pelvic pain but showed improvement in other outcome measures. At 24 weeks, 80.0% (12/15) maintained a favorable response; however, 3 patients experienced symptom recurrence around week 20 and requested retreatment. No serious adverse events were observed during treatment or follow-up periods. Conclusion: High-voltage, long-duration pulsed radiofrequency combined with ozone therapy showed preliminary efficacy and an acceptable safety profile for patients with refractory pudendal neuralgia. These findings are hypothesis-generating; prospective controlled studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.